

## Areas of Interest

We are interested in R&D and/or marketing collaboration in the following fields.

Perioperative  
(OR/ ICU/ ER/ Ward)

Palliative Care\*

Formulation  
Technology

Analgesics  
Sedatives  
Anti-emetics, etc.

Anesthetics  
Muscle Relaxant  
Cardiovascular, etc.

Controlled-release

New route of  
administration

\*Although perioperative field remains to be our top priority, we realize some of their products, such as analgesics and sedatives, could be used to improve QOL of patients in palliative care. Therefore, we are also putting palliative care into perspective.

*Attention: This presentation material is solely for the purpose of introducing our business activities to prospective business partners and NOT for the purpose of providing medical information to healthcare providers or patients.*

## Some of our Partners

Partner	Compound/ Product/ Technology	Collaboration
AbbVie Inc.	Sevoflurane	Out-License
Astellas Pharma Inc.	Balance <sup>®</sup> , Horizon <sup>®</sup> , Sosegon <sup>®</sup> , Suxamethonium	Transfer of Marketing and Manufacturing Rights
B. Braun Melsungen AG	Propofol	In-License
Cara Therapeutics	CR845 (Difelikefalin)	In-License
Daiichi Sankyo Co., Ltd.	Remifentanil	Co-Promotion
Deb Group Ltd.	Alcohol foam formulation technology	In-License
Faron Pharmaceuticals	FP-1201-lyo	In-License
Kissei Pharmaceutical Co., Ltd.	MR13A9 (CR845)	R&D and Marketing
Pfizer Japan Inc.	Precedex <sup>®</sup>	Co-Marketing
Sato Pharmaceutical Co., Ltd.	EMLA <sup>®</sup> Cream	Co-Promotion
UCB SA	Popscaine <sup>®</sup>	In-License

<sup>®</sup>represents trademark registered in Japan